Institute of Nephrology, Zhong Da Hospital, Southeast University, Nanjing, China.
Proteomics Clin Appl. 2008 Jul;2(7-8):989-96. doi: 10.1002/prca.200780134. Epub 2008 Jul 10.
Chronic kidney disease (CKD) that affects about 10% of the adult population has been shown as a worldwide public health problem in recent years. Both basic and clinical investigations have identified complex disease-associated protein networks involved in the pathophysiologic processes of CKD. The traditional single-assay approach and proteomic analysis of those related proteins have given birth to a steadily increasing panel of molecules that may have the potential to serve as biomarkers for CKD. However, both approaches suffered from some shortcomings from a technological point of view. Antibody microarray (AbM) is characterized by high sensitivity, specificity, and quantitative ability for a particular set of known proteins. However, its application in CKD has been very limited so far. The objective of this review, therefore, is to address the potential applications of AbM in studying of CKD. We will briefly discuss the proteins involved in the development of CKD, future directions in which AbM approaches would probably display its potential and also some key issues that need to be considered in application of this novel technique.
近年来，慢性肾脏病（CKD）影响了约 10%的成年人口，已成为全球公共卫生问题。基础和临床研究都已经确定了与 CKD 病理生理过程相关的复杂疾病相关蛋白网络。传统的单一检测方法和相关蛋白的蛋白质组学分析已经产生了大量可能作为 CKD 生物标志物的分子。然而，从技术角度来看，这两种方法都存在一些缺点。抗体微阵列（AbM）具有针对特定已知蛋白质组的高灵敏度、特异性和定量能力。然而，到目前为止，它在 CKD 中的应用非常有限。因此，本综述的目的是探讨 AbM 在 CKD 研究中的潜在应用。我们将简要讨论参与 CKD 发展的蛋白质，AbM 方法可能展示其潜力的未来方向，以及在应用这项新技术时需要考虑的一些关键问题。
